Table 7.
Pharmacodynamics of sCT after iv and pulmonary administration to rats.
| Formulation | Dose (µg kg−1) | AAC0–48 h (% h) | AAC0–48 h/dose (% h kg µg−1) |
Pharmacological activity relative to iv route (%) |
|---|---|---|---|---|
| iv solution of sCT | 5 | 211.05 ± 63.03 | 42.21 ± 12.61 | — |
| Pulmonary sCT solution | 25 | 302.08 ± 100.93 | 12.08 ± 4.04¥ | 28.63 ± 9.56 |
| Pulmonary blank nanoparticles | 25 | 25.10 ± 5.56 | 1.00 ± 0.22 | 2.4 ± 0.53 |
| Pulmonary sCT nanoparticles | 25 | 1259.95 ± 147.19 | 50.40 ± 5.89∗¥ | 119.4 ± 13.95 |
*Significant difference (P < 0.001) between iv solution of sCT and pulmonary sCT nanoparticles, ¥significant difference (P < 0.001) between pulmonary sCT solution and pulmonary sCT nanoparticles.